Pancreatic CancerCOPANNCT06713525
Observational Copenhagen Pancreatic Cancer Study
An observational study of Pancreatic Cancer, run by Inna Chen, MD at 1 site in Denmark.
Trial summary
The primary objective of the Copenhagen Pancreatic Cancer (COPAN) study is to describe the real-world population of patients with pancreatic cancer (PC). Larger sample of longitudinal real-world data provides a unique opportunity for comprehensive exploration of the diagnostic and treatment journey for individuals… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Pancreatic Cancer
- How many people
- 8,000 participants
- Where
- 1 siteDenmark
- Study dates
- 2 Feb 2025to 16 Dec 2036
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: All patients with pancreatic cancer referred to Department of Oncology, Herlev Hospital, Denmark within the study period will be invited to participate.
Who may be able to join
- Histologically confirmed pancreatic cancer
Who cannot join
- None
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Inna Markovna Inna Markovna Chen, MD, Herlev & Gentofte Hospital, MD contact
Denmark1 site, 1 recruiting
- Recruiting
Department of Oncology
Herlev, 2730
Inna Markovna Chen, MD, +45 38682898, Inna.Chen@regionh.dk
Inna.Chen@regionh.dk
About this study
Official title: Copenhagen Pancreatic Cancer Study (COPAN)
The primary objective of the Copenhagen Pancreatic Cancer (COPAN) study is to describe the real-world population of patients with pancreatic cancer (PC). Larger sample of longitudinal real-world data provides a unique opportunity for comprehensive exploration of the diagnostic and treatment journey for individuals diagnosed with PC and allows to investigate treatment outcomes and associated prognostic factors. Furthermore, the study aims to identify determinants of treatment management and treatment outcomes, including patient-reported outcomes.
Read the detailed description
The study objective is to describe the real-world population of patients with pancreatic cancer by collecting longitudinal data that facilitates a more rigorous understanding of the PC. This research project will catalog different elements of a patient's diagnostic and treatment journey and identify unmet needs of patients with PC.
The study aims to:
- To compile detailed demographic information of patients with PC.
- To document and analyze the clinical and disease characteristics at the time of diagnosis and beyond.
- To track various treatment modalities employed, including surgery, chemotherapy, and radiation therapy.
- To assess short-term and long-term outcomes, including survival rates, complications, and quality of life.
- To identify prognostic and predictive factors within the real-world cohort.
- To investigate the impact of PC and treatment on patients' quality of life.
4 Study Design This study of patients with PC will employ both a prospective, observational design and retrospective design to capture real-world data relating to health status and/or the delivery of health care routinely collected from a variety of sources. Data will be collected longitudinally, allowing for a dynamic analysis of the disease trajectory.
- Conditions
- Pancreatic Cancer
- Medical subject headings
- Pancreatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients with PC are referred to Comprehensive Pancreatic Cancer Center at Herlev Hospital | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall survival
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Dec 2024
- Study start2 Feb 2025
- Primary completion16 Dec 2035 (estimated)
- Study completion16 Dec 2036 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pancreatic CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 8,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Inna Chen, MD
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Inna Chen, MD, Herlev Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06713525
- Sponsor's protocol ID
- PA2416
- Acronym
- COPAN
- Status last verified
- Aug 2026
- First submitted
- 24 Nov 2024
- Last updated
- 4 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Copenhagen Pancreatic Cancer Study (COPAN)
- ClinicalTrials.gov ID
- NCT06713525
- Acronym / sponsor ID
- COPAN / PA2416
- Conditions
- Pancreatic Cancer
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 8,000 participants (estimated)
- Lead sponsor
- Inna Chen, MDUniversity, hospital or other
- Study start
- 2 Feb 2025 (actual)
- Primary completion
- 16 Dec 2035 (estimated)
- Study completion
- 16 Dec 2036 (estimated)
- First posted
- 3 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of the Copenhagen Pancreatic Cancer (COPAN) study is to describe the real-world population of patients with pancreatic cancer (PC). Larger sample of longitudinal real-world data provides a unique opportunity for comprehensive exploration of the diagnostic and treatment journey for individuals diagnosed with PC and allows to investigate treatment outcomes and associated prognostic factors. Furthermore, the study aims to identify determinants of treatment management and treatment outcomes, including patient-reported outcomes.
Detailed description
The study objective is to describe the real-world population of patients with pancreatic cancer by collecting longitudinal data that facilitates a more rigorous understanding of the PC. This research project will catalog different elements of a patient's diagnostic and treatment journey and identify unmet needs of patients with PC.
The study aims to:
- To compile detailed demographic information of patients with PC.
- To document and analyze the clinical and disease characteristics at the time of diagnosis and beyond.
- To track various treatment modalities employed, including surgery, chemotherapy, and radiation therapy.
- To assess short-term and long-term outcomes, including survival rates, complications, and quality of life.
- To identify prognostic and predictive factors within the real-world cohort.
- To investigate the impact of PC and treatment on patients' quality of life.
4 Study Design This study of patients with PC will employ both a prospective, observational design and retrospective design to capture real-world data relating to health status and/or the delivery of health care routinely collected from a variety of sources. Data will be collected longitudinally, allowing for a dynamic analysis of the disease trajectory.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with PC are referred to Comprehensive Pancreatic Cancer Center at Herlev Hospital | – | – |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All patients with pancreatic cancer referred to Department of Oncology, Herlev Hospital, Denmark within the study period will be invited to participate.
Key inclusion criteria (1 listed)
- Histologically confirmed pancreatic cancer
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Overall survival
Time frame: 3 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Pancreatic Cancer
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
RecruitingPhase 1
Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
RecruitingPhase 3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer, Pancreatic Cancer Metastatic
RecruitingPhase 3
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
Pancreatic Carcinoma, Pancreatic Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Inna Markovna Inna Markovna Chen, MD, Herlev & Gentofte Hospital, MD contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pancreatic Cancer, run by Inna Chen, MD at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Inna Markovna Inna Markovna Chen, MD, Herlev & Gentofte Hospital, MD (+45 3868-2898, Inna.Chen@regionh.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall survival (time frame: 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Sep 2026.